Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire all outstanding shares of Monogram for $4.04 per share in cash, valuing the deal at approximately $177 million in equity and $168 million enterprise value.
The acquisition is expected to be neutral to adjusted earnings per share in 2025 through 2027, turning accretive in 2028 and beyond.
Monogram Biosciences, Inc. common stockholders will receive a non-tradeable contingent value right, with potential cash payments up to $12.37 per share if specific milestones are met by 2030. The transaction is slated to close later this year.
This move broadens Zimmer Biomet’s extensive orthopedic robotics portfolio, enhancing solutions and analytics for surgeons before, during, and after operations.
Monogram’s technology marks a significant advancement, underscoring Zimmer Biomet’s commitment to leading innovation in surgical robotics and navigation, said Ivan Tornos, Chairman, President, and CEO.
